CONDENSED CONSOLIDATED STATEMENT OF EQUITY (Unaudited) - USD ($) $ in Thousands		Total	Stock Issued for Converted Debt	Stock Issued for Warrant Exercises	At-The-Market Offering	Private Placement	Controlled Equity Offering	Ideanomics Shareholders’ equity	Ideanomics Shareholders’ equity Stock Issued for Converted Debt	Ideanomics Shareholders’ equity Stock Issued for Warrant Exercises	Ideanomics Shareholders’ equity At-The-Market Offering	Ideanomics Shareholders’ equity Private Placement	Ideanomics Shareholders’ equity Controlled Equity Offering	Common Stock	Common Stock Stock Issued for Converted Debt	Common Stock Stock Issued for Warrant Exercises	Common Stock At-The-Market Offering	Common Stock Private Placement	Common Stock Controlled Equity Offering	Additional Paid-in  Capital	Additional Paid-in  Capital Stock Issued for Converted Debt	Additional Paid-in  Capital Stock Issued for Warrant Exercises	Additional Paid-in  Capital At-The-Market Offering	Additional Paid-in  Capital Private Placement	Additional Paid-in  Capital Controlled Equity Offering	Accumulated Deficit	Accumulated Other Comprehensive Loss	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2019														149,692,953
Beginning balance at Dec. 31, 2019		$ 58,737						$ 33,559						$ 150						$ 282,554						$ (248,481)	$ (664)	$ 25,178	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		2,202						2,202												2,202
Common stock issuance for professional fees (in shares)														429,000
Common stock issuance for professional fee		240						240												240
Common stock issuance for convertible notes (in shares)														1,454,424
Common stock issuance for convertible note		614						614						$ 1						613
Common stock issuance for acquisition (in shares)														10,883,668
Common stock issuance for acquisition		6,748						6,748						$ 11						6,737
Common stock issuance (in shares)														1,000,000
Common stock issuance		1,000						1,000						$ 1						999
Measurement period adjustment		(11,454)																										(11,454)	[1]
Non-controlling shareholder contribution		100																										100	[1]
Net income (loss)		(12,726)						(12,348)																		(12,348)		(378)	[1]
Foreign currency translation adjustments, net of nil tax		7						(16)																			(16)	23	[1]
Ending balance (in shares) at Mar. 31, 2020														163,460,045
Ending balance at Mar. 31, 2020		45,468						31,999						$ 163						293,345						(260,829)	(680)	13,469	[1]
Beginning balance (in shares) at Dec. 31, 2019														149,692,953
Beginning balance at Dec. 31, 2019		$ 58,737						33,559						$ 150						282,554						(248,481)	(664)	25,178	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issuance for professional fees (in shares)		1,200,000
Common stock issuance (in shares)																		34,500,000
Changes in fair value of available-for-sale securities		$ 0
Foreign currency translation adjustments, net of nil tax		1,639
Ending balance (in shares) at Sep. 30, 2020														238,871,366
Ending balance at Sep. 30, 2020		80,502						67,182						$ 239						362,346						(295,693)	290	13,320	[1]
Beginning balance (in shares) at Mar. 31, 2020														163,460,045
Beginning balance at Mar. 31, 2020		45,468						31,999						$ 163						293,345						(260,829)	(680)	13,469	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		3,394						3,394												3,394
Common stock issuance for professional fees (in shares)														515,942
Common stock issuance for professional fee		309						309						$ 1						308								0	[1]
Common stock issuance for convertible notes (in shares)															26,231,634	6,995,906
Common stock issuance for convertible note			$ 20,009	$ 5,628					$ 20,009	$ 5,628					$ 26	$ 7					$ 19,983	$ 5,621
Common stock issued to settle debt (in shares)														4,577,876
Common stock issued to settle debt		2,314						2,314						$ 5						2,309
Common stock issuance for acquisition (in shares)														459,180
Common stock issuance for acquisition		293						293												293
Common stock issuance (in shares)														34,473,719
Common stock issuance		32,502						32,502						$ 35						32,467
Measurement period adjustment		(131)																										(131)	[1]
Common stock issued under employee stock incentive plan (in shares)														293,857
Net income (loss)	[2]	(26,711)						(26,578)																		(26,578)		(133)	[1]
Foreign currency translation adjustments, net of nil tax		276						172																			172	104	[1]
Ending balance (in shares) at Jun. 30, 2020														237,008,159
Ending balance at Jun. 30, 2020		83,351						70,042						$ 237						357,720						(287,407)	(508)	13,309	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		$ 3,252						3,252												3,252
Common stock issuance for professional fees (in shares)		300,000												250,000
Common stock issuance for professional fee		$ 343						343												343
Common stock issuance for acquisition (in shares)														1,613,207
Common stock issuance for acquisition		1,033						1,033						$ 2						1,031
Changes in fair value of available-for-sale securities		0
Net income (loss)		(8,833)						(8,286)																		(8,286)		(547)	[1]
Foreign currency translation adjustments, net of nil tax		1,356						798																			798	558	[1]
Ending balance (in shares) at Sep. 30, 2020														238,871,366
Ending balance at Sep. 30, 2020		80,502						67,182						$ 239						362,346						(295,693)	290	13,320	[1]
Beginning balance (in shares) at Dec. 31, 2020														344,861,295
Beginning balance at Dec. 31, 2020		193,022						186,584						$ 345						531,866						(346,883)	1,256	6,438	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		2,040						2,040												2,040
Common stock issuance for professional fees (in shares)														440,909
Common stock issuance for professional fee		1,162						1,162												1,162
Common stock issuance for convertible notes (in shares)														45,895,763
Common stock issuance for convertible note		140,126						140,126						$ 46						140,080
Common stock issuance for acquisition (in shares)														10,181,299
Common stock issuance for acquisition		32,377						32,377						$ 10						32,367
Common stock issuance (in shares)														17,615,534
Common stock issuance		53,407						53,407						$ 18						53,389
Common stock issued under employee stock incentive plan (in shares)														475,000
Common stock issued under employee stock incentive plan		251						251												251
Net income (loss)		(6,692)						(6,412)																		(6,412)		(280)	[1]
Foreign currency translation adjustments, net of nil tax		(860)						(472)																			(472)	(388)	[1]
Ending balance (in shares) at Mar. 31, 2021														419,469,800
Ending balance at Mar. 31, 2021		414,833						409,063						$ 419						761,155						(353,295)	784	5,770	[1]
Beginning balance (in shares) at Dec. 31, 2020														344,861,295
Beginning balance at Dec. 31, 2020		193,022						186,584						$ 345						531,866						(346,883)	1,256	6,438	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issuance (in shares)																		10,000,000
Common stock issuance																		$ 27,300
Changes in fair value of available-for-sale securities		(16)
Foreign currency translation adjustments, net of nil tax		(1,196)
Ending balance (in shares) at Sep. 30, 2021														481,901,523
Ending balance at Sep. 30, 2021		532,604						527,626						$ 483						938,006						(411,409)	546	4,978
Beginning balance (in shares) at Mar. 31, 2021														419,469,800
Beginning balance at Mar. 31, 2021		414,833						409,063						$ 419						761,155						(353,295)	784	5,770	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		2,007						2,007												2,007
Common stock issuance for professional fees (in shares)														260,000
Common stock issuance for professional fee		656						656												656
Common stock issuance for acquisition (in shares)														6,733,497
Common stock issuance for acquisition		21,127						21,127						$ 7						21,120
Common stock issuance (in shares)																	25,301,190	10,000,000
Common stock issuance					$ 74,347	$ 27,300					$ 74,347	$ 27,300					$ 25	$ 10					$ 74,322	$ 27,290
Changes in fair value of available-for-sale securities		(20)						(20)																			(20)
Common stock issued under employee stock incentive plan (in shares)														4,590,000
Common stock issued under employee stock incentive plan		7,740						7,740						$ 5						7,735
Net income (loss)		(7,582)						(7,263)																		(7,263)		(319)	[1]
Foreign currency translation adjustments, net of nil tax		(41)						(34)																			(34)	(7)	[1]
Ending balance (in shares) at Jun. 30, 2021														466,354,487
Ending balance at Jun. 30, 2021		540,367						534,923						$ 466						894,285						(360,558)	730	5,444	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation		15,187						15,187												15,187
Common stock issuance for acquisition (in shares)														2,011,617
Common stock issuance for acquisition		6,305						6,305						$ 2						6,303
Common stock issuance (in shares)																	7,495,997		1,988,401
Common stock issuance					$ 17,744		$ 4,203				$ 17,744		$ 4,203				$ 7		$ 2				$ 17,737		$ 4,201
Changes in fair value of available-for-sale securities		4						4																			4
Common stock issued under employee stock incentive plan (in shares)														4,051,021
Common stock issued under employee stock incentive plan		299						299						$ 6						293
Net income (loss)		(51,210)						(50,851)																		(50,851)		(359)
Foreign currency translation adjustments, net of nil tax		(295)						(188)																			(188)	(107)
Ending balance (in shares) at Sep. 30, 2021														481,901,523
Ending balance at Sep. 30, 2021		$ 532,604						$ 527,626						$ 483						$ 938,006						$ (411,409)	$ 546	$ 4,978

[1] Excludes accretion of dividend for redeemable non-controlling interest.

[2] Excludes deemed dividend related to warrant repricing